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Abstract: An increasing body of literature from genome-
wide association studies and human whole-genome
sequencing highlights the identification of large numbers
of candidate regulatory variants of potential therapeutic
interest in numerous diseases. Our relatively poor
understanding of the functions of non-coding genomic
sequence, and the slow and laborious process of
experimental validation of the functional significance of
human regulatory variants, limits our ability to fully
benefit from this information in our efforts to compre-
hend human disease. Humanized mouse models
(HuMMs), in which human genes are introduced into
the mouse, suggest an approach to this problem. In the
past, HuMMs have been used successfully to study human
disease variants; e.g., the complex genetic condition
arising from Down syndrome, common monogenic
disorders such as Huntington disease and b-thalassemia,
and cancer susceptibility genes such as BRCA1. In this
commentary, we highlight a novel method for high-
throughput single-copy site-specific generation of HuMMs
entitled High-throughput Human Genes on the X
Chromosome (HuGX). This method can be applied to
most human genes for which a bacterial artificial
chromosome (BAC) construct can be derived and a
mouse-null allele exists. This strategy comprises (1) the
use of recombineering technology to create a human
variant–harbouring BAC, (2) knock-in of this BAC into the
mouse genome using Hprt docking technology, and (3)
allele comparison by interspecies complementation. We
demonstrate the throughput of the HuGX method by
generating a series of seven different alleles for the human
NR2E1 gene at Hprt. In future challenges, we consider the
current limitations of experimental approaches and call for
a concerted effort by the genetics community, for both
human and mouse, to solve the challenge of the functional
analysis of human regulatory variation.
Introduction
A decade ago, the Human Genome Project published its first
human DNA sequence draft, followed shortly by the full version
in 2003 [1–3]. This project and the SNP Consortium and the
International HapMap Project have provided geneticists with
invaluable tools for their research on human populations [4,5].
Their activities have resulted in an exponential growth of
PubMed entries related to genome-wide association studies
(GWASs) plus human whole-genome sequencing (HWGS) over
the past decade (Figure 1, white bars). The increasing numbers of
studies cumulated at 2,649 entries in 2010; these studies mainly
focused on understanding the genetic variants affecting the
development of diseases and disorders in humans. For obvious
reasons, protein-coding variants have been the most extensively
studied so far. However, an increasing body of literature from
GWASs and candidate gene association studies also highlights
the identification of candidate regulatory variants of potential
therapeutic interest in numerous diseases [6–14]. Furthermore,
with the cost of HWGS being driven down by cheaper
sequencing technologies, we envision a continuing large increase
in the identification of candidate regulatory variants. In general,
the biological role of variants found in putative regulatory
regions is harder to predict than that for protein-coding variants,
in part because of our poor understanding of the functions of
non-coding genomic sequence, and the slow and laborious
process of experimental validation of the functional significance
of human regulatory variants. In this commentary, we will review
current efforts at modelling human variation in mouse and
highlight a novel method for high-throughput generation of
humanized mouse models (HuMMs) entitled High-throughput
Human Genes on the X Chromosome (HuGX, pronounced
‘‘hugs’’).
Typical Humanized Mouse Models Are Powerful
but Not Ideal for Regulatory Variants
It is always important to remember that mice are not ‘‘little
humans’’, and that species-specific differences limit the value of
any model organism. Nevertheless, throughout history, the
laboratory mouse has been the human disease model of choice
for geneticists, in part because of the rapid breeding rate of mice,
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spontaneous-mutation-harbouring strains. Contributing to the
mouse as a model was the advancement in embryonic technol-
ogies, allowing the engineering of the mouse genome and resulting
in the generation of transgenic random-insertion, knock-out, and
knock-in mouse models. Furthermore, the laboratory mouse
genome sequence was released in 2002 and demonstrated that
99% of mouse genes have human homologues, strengthening the
importance of mouse models in probing human biology and
disease [15–17]. This importance has been reflected by a
continually growing literature describing novel mouse models
over the past decade (Figure 1, grey bars). However, in contrast to
coding regions, human–mouse comparative genomic analysis
demonstrated a lower level of conservation in putative regulatory
regions of the genome [15]. This finding strengthened a hypothesis
posed more than 25 years ago suggesting that regulatory regions
may play a crucial role in underlying species differences and
human-specific biology and disease [18]. It also raises a problem
for mouse modelling when a strictly mouse-genome-based
approach is used to validate human candidate regulatory variants,
since the equivalent DNA sequence and/or epigenomic environ-
ment may not be present.
HuMMs, in which human genes are introduced into the mouse,
suggest an approach to this problem. Surprisingly, the number of
entries in the literature for HuMMs is very modest when
compared to the two previous categories (Figure 1, black bars).
Many of the HuMM entries are not genetic per se but are related
to immunity studies—using human cells or tissues engrafted in
nude mice—and thus are unrelated to the data generated by
GWASs and HWGS. Nevertheless, there are numerous examples
of successful genetic HuMMs.
A HuMM approach was used to study the complex genetic
condition arising from Down syndrome, also known as trisomy 21.
This syndrome results from an altered dosage of wild-type (WT)
genes on human Chromosome 21, a phenomenon that can be
mimicked by generating trans-species aneuploid mice carrying a
human chromosome [19]. In this example, the mouse strain
generated contained an estimated 92% of all known human
Chromosome 21 genes, and a large-scale analysis demonstrated
that 81% of human Chromosome 21 genes were expressed in
mouse tissues [19,20]. Additional investigation, using a set of
conserved and well-characterized transcription factors responsible
for hepatocyte development and function, revealed that genetic
sequence rather than interspecies differences in epigenetic
machinery or cellular environment is largely responsible for
directing transcriptional programs [21]. These results demonstrat-
ed that human gene regulation is generally conserved in mice,
strengthening the argument that HuMMs can be a good approach
for understanding the role of candidate regulatory variants in
disease development.
Other examples of successful HuMMs to study the role of
genetic mutations are found in common monogenic disorders such
as Huntington disease and b-thalassemia, as well as cancer
susceptibility genes such as BRCA1 [22–25]. All of these WT
human genes in HuMMs successfully rescued the embryonic lethal
phenotype from the mouse gene knock-out animals, thereby
providing valuable information regarding the human gene
function by demonstrating an interspecies complementation of
the human gene in the mouse null background. This complemen-
tation was due not only to the similarity of the genes in terms of
protein function, but also to the identical tissue expression
distribution of the human gene [22–25]. This was surprising
considering the low percentage of identity between human and
mouse for some of these genes in both the regulatory and coding
sequences [25].
These results were invaluable, as they demonstrated that
HuMMs can be used to study the biological role of mutant forms
of these human genes. In the case of Huntington disease, this line
of investigation has led to the generation of several human yeast
artificial chromosome (YAC)–harbouring strains to study the
biological implication of expanded glutamine repeats in Hunting-
ton disease development [26–28]. Advancements in site-specific
bacterial artificial chromosome (BAC) mutagenesis techniques
supported the shift to generation of BAC-based mutation-
harbouring mouse models [29–32]. These included the generation
of HuMMs harbouring codon-specific mutations for b-thalassemia
and the BRCA1 cancer susceptibility gene. These HuMMs
provided information regarding the biological implication of such
mutations and their potential underlying role in human health
[33,34]. However, the approaches used to generate these HuMMs,
which were suitable when protein-coding variants were being
tested, encountered serious limitations in probing the role of
human candidate regulatory variants.
In general, HuMM generation has used microinjection of DNA
into zygotic pronuclei [35–37]. This technique is widely used in
the field of mammalian genetics, but is not without limitations. For
one, it requires extensive characterization of the different founder
lines to control for variability in gene expression, a phenomenon
Figure 1. The literature is increasing more slowly for human-
ized mouse models than for GWASs and HWGS or novel mouse
models. Interrogation of the PubMed literature database (http://www.
ncbi.nlm.nih.gov/pubmed) reveals a faster growing body of literature
related to GWASs and HWGS (white bars) or novel mouse models (grey
bars) than to HuMMs (black bars). Interrogation of the database was
done using the online search option from EndNote (http://www.
endnote.com/). Individual numbers of entries for the search terms
‘‘genome wide association studies’’ and ‘‘human whole genome
sequencing’’ were added together for the figure. Search terms for
novel mouse models were ‘‘novel knockout mouse’’, ‘‘novel knockin
mouse’’, and ‘‘novel knock-in mouse’’. The entries for the search term
‘‘humanized mouse models’’ were not restricted to genetic mouse
models but included xenograft mouse models as well. Search terms
were interrogated in ‘‘all fields’’ per year.
doi:10.1371/journal.pgen.1002544.g001
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of insertion (i.e., position effect) and the number of copies often
found tandemly inserted (i.e., copy effect) [38–41]. The transgene
can potentially lead to disruption of endogenous gene function and
repeat-induced gene silencing, two factors that must be taken into
account when generating mice by random-insertion pronuclear
injection [42]. Since each strain is unique, reproducibility between
the different mouse strains becomes a major limiting factor when
using random insertion as a mean to generate HuMMs. This lack
of reproducibility is less than ideal for any comparison between
transgenes in different mouse strains, but is particularly concerning
when probing for candidate regulatory variant differences. The
ideal method would control for both the site of insertion and the
copy numbers inserted in the genome.
Excellent Techniques Exist for Single-Copy Non-
Random Docking in the Mouse Genome
One type of approach, which allows single-copy insertion in the
genome, includes the use of retroviruses and transposon activity
[43–45]. Although quite successful, this approach has limitations
as it does not provide controls for the site of insertion in the
genome, leading to variability in expression due to genomic
environment, as well as potential disruption of endogenous genes.
Another potentially powerful approach, called recombinase-
mediated genomic replacement, allows the cre-based insertion of
a human gene at the site of, and replacing, the endogenous mouse
gene [46]. This approach provides stringent control over the
genomic environment surrounding the insertion site. However, the
method simultaneously creates two inseparable genetic events in
the same gene: (1) heterozygosity at the mouse locus and (2)
addition of the human gene. Thus, the human gene can be studied
only on the heterozygous mutant mouse background. Other
limitations include the fact that the replacement is a low-frequency
event, and the ‘‘gene by gene’’ approach will restrict throughput.
Another novel approach was described recently using pronuclear
injection coupled to integrase activity to achieve single-copy site-
specific insertion in the mouse genome [47]. This approach used
wC31-integrase-mediated recombination activity between attB sites
from recombinant DNA with attP sites previously inserted at a
specific locus in the mouse genome. Although also quite
promising, this approach yielded up to 40% site-specific
integration at best, and was only tested on small construct
plasmids, another limitation, since many genes require large
constructs [47].
Traditionally, two mouse genes have been used as genomic
docking sites: the autosomal Rosa26 (reverse orientation splice acceptor
26) and X chromosome Hprt (hypoxanthine guanine phosphoribosyl
transferase) [48,49]. The Rosa26 locus has most often been used to
dock constructs when strong ubiquitous expression is required
[50–54]. Plasmid-size docking is readily achieved; however, large
BAC insertions have not been reported. Also, insertion at the
Rosa26 locus typically results in disruption of the gene, which in
turn may lead to mild phenotypic consequences [55]. Use of the
Hprt docking site has also been widely reported in the literature,
and despite the wide expression of Hprt itself, this locus is more
often chosen for tissue- or cell-type-specific expression of the
targeted construct [56–58]. This locus readily accepts plasmid-size
constructs but also large (.200 kb) BAC constructs [48,56]. In the
past, docking has been done in such a way that it disrupts the Hprt
gene, resulting in mice with a mild phenotype [59–61]. However,
this disruption is now typically avoided by a strategy that uses
embryonic stem cells (ESCs) that already carry a spontaneous
deletion of the 59 end of the Hprt gene [62]. In this strategy,
docking involves construct insertion 59 of Hprt and repairing the
expression of the Hprt gene itself [56,57,63]. This repair of Hprt
enables direct selection of high-frequency correctly targeted ESC
clones [63].
GWASs and HWGS Require High-Throughput
Humanized Mouse Models
Huge strides have been made bringing high throughput to
mouse functional genomics. One such stride is simple and highly
efficient BAC recombineering in Escherichia coli [31,64,65]. This
technology provides researchers with limitless possibilities for DNA
modification via homologous recombination in E. coli. It employs
the BAC-adapted strain harbouring a defective lambda prophage
that allows the recombination genes exo, bet, and gam to be
expressed under the control of a temperature-sensitive l cI-
repressor [31,64–66]. DNA modification possibilities include
insertion of exogenous DNA fragments in the endogenous BAC
DNA, size-specific DNA deletion, single-base-pair-specific DNA
alteration, and BAC fusion (i.e., recombining overlapping BAC
constructs into a single, larger BAC) [30,31,66,67]. Hence,
generation of any variant-harbouring allele in a high-throughput
manner can be easily achieved using this technology. Such
approaches are already being adopted by large-scale mouse knock-
out programmes such as the International Knockout Mouse
Consortium [68].
Another stride is the generation of important resources by the
currently ongoing large-scale mouse projects [58,68,69]. For
example, the International Knockout Mouse Consortium is
generating ESC-targeted mutations in all protein-coding genes
[68]. This resource will have many impacts, but specific to this
discussion, it enables complementation approaches to be under-
taken for most human genes. To date, this group has generated
16,878 targeted alleles in germline-competent C57BL/6N ESCs
(http://www.knockoutmouse.org) [68,70–72].
Finally, C57BL/6 is the most widely used inbred mouse strain
and one of the best characterized [68]. The increasing use of ESCs
derived from this strain, especially by large-scale projects, will
greatly reduce the need for backcrossing by projects using this
mouse strain, thus increasing the throughput of most projects [68].
Even with these game-changing strides, HuMM generation will
never achieve the throughput of array and sequence technologies.
Thus, variants identified by GWASs and HWGS will always need
to be extensively pre-screened as strong candidate regulatory
variants and suitable for cross-species analysis before entering a
HuMM project pipeline.
HuGX for High-Throughput Assaying of Human
Candidate Regulatory Variants
Here we present an approach, HuGX, aimed at understanding
the role of candidate human regulatory variants in the develop-
ment of human diseases and disorders. The strategy comprises (1)
the use of the BAC-adapted recombineering technology to create a
human-variant-harbouring BAC, (2) knock-in of this BAC into the
mouse genome using Hprt docking technology, and (3) allele
comparison by interspecies complementation. This approach can
be applied to human genes for which an expressing BAC construct
can be derived, which can complement at least a component of a
mouse phenotype.
The first step is to find a suitable BAC for ‘‘your favourite gene’’
(YFG). This BAC should be computationally analyzed to
determine the likelihood that it includes the entire coding sequence
as well as 59 and 39 regulatory sequences. The GENSAT project,
PLoS Genetics | www.plosgenetics.org 3 March 2012 | Volume 8 | Issue 3 | e1002544Figure 2. Strategy for high-throughput human genes on the X chromosome (HuGX). (A) Flow diagram representing the major steps of the
HuGX strategy, which builds on previous methods [56,74]. Starting with a human BAC carrying your favourite gene (YFG) from the RPCI-11 library, for
example, two retrofitting steps are employed: (1) addition of the HPRT homology regions for recombination (WT-YFG) and (2) introduction of your
favourite regulatory variant (YFRV) into YFG (YFRV-YFG). In this example the resulting BAC YFRV-YFG is linearized, typically using I-SceI, and
electroporated into ESCs. 129P2/OlaHsd, B6129F1 hybrid, and C57BL/6NTac ESCs are all available carrying the 36-kb (Hprt
b-m3) deletion used for
docking. Selection of homologous recombinant clones is performed using hypoxanthine-aminopterin-thymidine medium, and clones carrying
correctly targeted complete-BAC inserts are injected into blastocysts to generate chimeras. Schematic, not to scale. (B) Details of knock-in 59 of the
Hprt locus on X chromosome. The linearized BAC construct is introduced into the Hprt
b-m3 deletion by electroporation. Hprt gene expression is
restored by the presence of the human HPRT promoter (hP), first exon (h1), and second mouse exon (m2). Mouse homology arms (blue); Hprt coding
regions (red); vector backbone (narrow yellow line); SacB gene from BAC vector backbone (brown); 59 and 39 untranslated regions of YFG (orange);
YFRV (yellow); coding region of YFG (green); hP (black arrow); h1 (grey); m2 and m3 (black). Schematic, not to scale. (C) Breeding strategy to achieve
complementation. Assuming the genetic background is suitable, male chimeras can immediately be bred to females heterozygous for a null allele at
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genics, reports ,85% endogenous-like expression for genes
#100 kb [69,73]. Since ,86% of human genes are #100 kb
(Ensemble assembly, February 2009, GRCh37/hg19), we estimate
there will be suitable BACs for ,75% of them. In addition,
recombineering approaches are available to fuse two BACs, isolate
only the 59 region, or delete unwanted sequences (e.g.,
neighbouring genes) as needed [67]. Alternatively, the recombi-
neering technology can be applied to a human P1 artificial
chromosome should YFG be small [30,66]. Our approach
highlights the use of the RPCI-11 Human Male BAC Library
(http://bacpac.chori.org/hmale11.htm), which was built in the
pBACe3.6 vector (Figure 2A). The backbone of this BAC vector
contains a SacB gene that can be used as a targeting site for the first
retrofitting step, adding the HPRT homology regions from
plasmids pJDH8A/246b or the pEMS1306 series [56,58,74].
This BAC construct can then be used as the substrate for
subsequent retrofitting steps, to add ‘‘your favourite regulatory
variant’’ (YFRV), a DNA insertion, deletion, or single-base-pair
alteration as needed. These retrofitting steps can be carried out in
a high-throughput manner to rapidly develop an allele series of
different variants to be tested. Since, both the WT-YFG and YFRV-
YFG BAC constructs contain the homology regions that allow
proper targeting at the Hprt locus, each can be electroporated into
ESCs and selected in hypoxanthine-aminopterin-thymidine (HAT)
medium, and homologous recombinant clones can be identified
and microinjected into mouse embryos (Figure 2A and 2B) [63].
Male chimeras are bred to generate germline females that carry a
site-specific single-copy WT-YFG BAC, or YFRV-YFG BAC, on
their X chromosome. Assuming the genetic background is suitable,
genetic complementation can be tested immediately by performing
two generations of mating (Figure 2C). The resulting animals will
carry a single copy of the human WT-YFG,o rYFRV-YFG BAC, on





YFRV-YFG/Y). Animals studied on the null background will be
males, thus avoiding X inactivation [56,75]. Using this HuGX
strategy, the phenotype of the Yfg
2/2, Hprt
YFRV-YFG/Y animals can
be directly compared to that of the Yfg
2/2, Hprt
WT-YFG/Y animals.
Regardless of whether interspecies complementation is complete
or partial, any differences can be attributed to the function of the
human variant.
We have recently used this approach to generate a directly
comparable allele series for our favourite gene, nuclear receptor 2E1
(NR2E1). This gene encodes an orphan nuclear receptor (also
known as TLX) that is highly conserved between human and
mouse, and has an important role in the maintenance of the
neural/progenitor stem cell populations of both the forebrain and
retina [76–80]. Nr2e1-null mice have brain and eye abnormalities
such as hyperactivity, extreme aggressive behaviours, and
blindness [81–83]. These phenotypes can be rescued by human
NR2E1 under its endogenous promoter, thereby demonstrating
the functional equivalence of the human and mouse genes in
mouse [81,84]. Recently, positive association results between
NR2E1 and bipolar disorder have been reported, along with an
increase in detection of rare variants in patients [85]. The
objective of our approach was to generate seven human alleles
knocked in to mouse, including one harbouring a human WT
BAC, an ,2-kb regulatory deletion, four single-base-pair
candidate regulatory variants, and one two-base-pair candidate
regulatory variant (Figure 3A). Recombineering and targeting of
these constructs at the Hprt locus was performed. As shown by
others and our own data (Figure 3A), it is important to molecularly
characterize the integrity of the BAC insertions [56]. Nevertheless,
the low number of clones that needed to be picked per construct,
and the high percentage of correctly targeted clones, which varied
from 13% to 73% with an average of 48%, highlights the ease of
this strategy and its applicability to high throughput.
Mouse strains were generated from these different constructs,
and species-specific reverse transcription PCR (RT-PCR) assays
on different tissue samples were performed for four of these mouse
strains (WT, Deletion [g.21943 to g.220], G.C [g.2078], and
C.G [g.14122]) (Figure 3B). These assays demonstrated expres-
sion of the human NR2E1 BACs in the eyes, forebrain, and
midbrain of adult mice, and the absence of expression in the adult
heart, lung, and liver (Figure 3B). These results, when compared to
the mouse endogenous Nr2e1 expression pattern, suggest endog-
enous-like tissue-specific expression of the human NR2E1 BACs in
the mouse strains. Backcrossing to the appropriate background
and subsequent crossing to the Nr2e1-null background will allow us
to evaluate the importance of these variants in the development of
diseases and disorders.
Overall, generation of these seven strains has demonstrated that
six to nine months is necessary to generate a single HuGX mouse
model. Since the components of the HuGX methodology are
scalable, and applicable to a large-scale parallel approach, this
strategy is suitable for high-throughput mouse model generation to
study the relevance of candidate mutations.
Challenges for the Future
The exponential growth of data in the literature coming from
GWASs and HWGS requires novel high-throughput approaches
to test the biological importance of the large numbers of variants
being identified, particularly candidate regulatory variants. In
considering experimental approaches, three challenges face our
field. The first is a consideration of the balance between construct
flexibility and size. Small plasmid-based constructs lead in
flexibility, especially with the option of DNA synthesis, allowing
the efficient generation of any desired sequence [86]. But plasmids
will almost certainly fail to capture the genomic context of the
regulatory variant, especially factors such as the chromatin
structure. BACs are often gene-sized (holding ,200 kb) and are
relatively easily manipulated by recombineering, and so are the
construct of choice for many large projects, e.g., the GENSAT
project and the International Knockout Mouse Consortium
[30,68,69]. However, some human genes can span more than
one megabase (e.g., dystrophin) [87–89]. YACs can accommodate
this size of genomic DNA, and site-specific mutagenesis can be
readily performed using the homologous recombination system of
the yeast [90]. However, site-specific docking of YAC constructs is
beyond our current abilities and makes YACs presently unsuitable
for high-throughput single-copy approaches. The second challenge
is a consideration of docking sites and technology. The Hprt locus
provides a reliable and highly efficient docking site for BAC
insertion into the mouse genome. The position of this locus on the
X chromosome can be an advantage, i.e., all female offspring of a
carrier male are carriers, but also a disadvantage, i.e., X
inactivation in females results in mosaic expression in heterozy-
the mouse copy of Yfg (Yfg
+/2) to generate germline females heterozygous for Yfg (Yfg
+/2) and Hprt
YFRV-YFG/+. On the other hand, assuming the
challenging situation in which no heterozygous phenotype exists to complement, these females will be mated with a Yfg
+/2male, resulting in males
for study carrying a single copy of the human retrofitted Hprt
YFRV-YFG and the mouse null (Yfg
2/2) gene.
doi:10.1371/journal.pgen.1002544.g002
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the human gene. Although the Hprt locus has been used to dock
the largest fragments yet into the genome, up to 200 kb, size is still
a limiting factor for certain human genes [56]. Hence, the
generation of an alternative autosomal docking site that does not
disrupt a gene, and allows insertion of large DNA fragments,
would be ideal in the near future. The third challenge is a
consideration of the value of stem cells and in vitro differentiation
to assay candidate regulatory variant function. Mouse ESCs, as
already described, can be derived to carry a matched pair of
human alleles that differ only by the variant. Assuming an
appropriate differentiation protocol [91,92], differences in expres-
Figure 3. High-throughput generation of regulatory allele series. (A) Human BAC RP11-144P8 was retrofitted seven times to generate the
different regulatory variants (column 1). The method of retrofitting (column 2), targeting (column 3), and variant screening (column 4) is presented for
each variant. Also given are the number of ESC clones isolated after electroporation (column 5), the number of correctly targeted clones after PCR
validation using assays an average of 6 kb, and a maximum of 11 kb, apart (column 6), and the resulting percentage of correctly targeted clones
(column 7). (B) Species-specific reverse transcriptase PCR demonstrates transcription from the human BAC in germline animals from four of the strains
generated by the high-throughput approach. One-step reverse transcription PCR reactions were performed using oligonucleotides specific for
human NR2E1, mouse Nr2e1, and mouse Gapdh. The results show, as expected, expression of the human NR2E1 gene in adult eye, forebrain, and
midbrain, but not in adult lung, heart, and liver. Marker, 100-bp ladder; positive control (Ctl+), human RNA for human NR2E1 assay and mouse RNA for
mouse Nr2e1 and Gapdh assays; negative control (Ctl2), human RNA for mouse Nr2e1 and Gapdh assays and mouse RNA for human NR2E1 assay.
doi:10.1371/journal.pgen.1002544.g003
PLoS Genetics | www.plosgenetics.org 6 March 2012 | Volume 8 | Issue 3 | e1002544sion in almost any cell type could be detected, and this would add
to the overall understanding of the variant. However, generation
of such in vitro data alone would presumably be less successful in
leading to an understanding of human disease, than when
accompanied by information on the in vivo phenotype of mice
derived from these same cells. A species-relevant, powerful in vitro
assay can be envisaged for the near future when it would be
possible to derive a matched pair of human-induced pluripotent
stem cells, differing only by the variant. However, it would still
remain necessary to undertake an in vivo analysis using HuMM or
HuGX mice to comprehensively study the variant.
We conclude by calling for a concerted effort by the genetics
community, those studying human and mouse, to move forward to
solve the challenge of functional analysis of human regulatory
variation in human disease and disorders.
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